collection
https://read.qxmd.com/read/36171828/psychedelics-their-limited-understanding-and-future-in-the-treatment-of-chronic-pain
#1
REVIEW
Vedant N Hedau, Ashish P Anjankar
Psychedelics are hallucinogenic drugs that alter the state of consciousness substantially. They bring about psychological, auditory, and visual changes. The psychedelics act on the brain, implying that they have a powerful psychological impact. One of the main factors contributing to disability worldwide is pain. The majority of people deal with pain on a daily basis. Living with chronic pain affects daily life and has social implications. Chronic pain can be associated with any disease that may be genetic, idiopathic, or traumatic...
August 2022: Curēus
https://read.qxmd.com/read/35315749/magic-mushroom-use-a-qualitative-interview-study-of-post-trip-impacts-and-strategies-for-optimizing-experiences
#2
JOURNAL ARTICLE
Lindsay Shaw, Kerri Rea, Nathan J Lachowsky, Eric Abella Roth
The field of psychedelic research is undergoing a revival, yet research focused on non-clinical psychedelic use remains relatively limited. The current qualitative study sheds light on how people use magic mushrooms, what they perceive the effects of such use to be, and the meanings that users attach to their magic mushroom experiences. To be eligible to participate in the study, participants were required to be young adults who had used magic mushrooms within the past three months and residents of Victoria, Canada...
March 22, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35318904/how-important-is-a-guide-who-has-taken-psilocybin-in-psilocybin-assisted-therapy-for-depression
#3
JOURNAL ARTICLE
Mitch Earleywine, Fiona Low, Brianna R Altman, Joseph De Leo
Promising outcomes of Psilocybin-Assisted Therapy (PAT) for depression have generated concerted efforts to replicate, extend, and refine protocols to maximize efficacy. Psychotherapy research reveals that clients benefit most when important components of treatment align with their personal preferences. One open question related to PAT concerns the importance of the psilocybin experience of the guides (trained professionals present during acute effects). We sought to assess the importance of a guide who had used psilocybin to potential clients with depressive symptoms...
March 23, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35438609/psychedelic-experiences-and-mindfulness-are-associated-with-improved-wellbeing
#4
JOURNAL ARTICLE
Tianhong Tim Qiu, John Paul Minda
Both psychedelics and mindfulness are recently emerging topics of interest in academia and popular culture. The Prevalence of personal meditation practices and recreational psychedelic use has consistently increased in the past decade. While clinical work has shown both to improve long-term wellbeing, data on naturalistic applications of psychedelics and mindfulness are lacking. The current study examined the relationship between psychedelic use, mindfulness, and multi-faceted wellbeing as an outcome. Hierarchical regression was used to quantify these associations on a sample of people (N = 1,219) who engage in both meditation practices and psychedelic use...
April 19, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35506737/ayahuasca-ritual-personality-and-sociality-observational-research-conducted-in-a-substance-use-disorder-rehabilitation-center-in-uruguay
#5
JOURNAL ARTICLE
Ismael Apud, Juan Scuro, Ignacio Carrera, Andrés Oliveri
The current article presents a mixed qualitative-quantitative observational study of the effect of ayahuasca ritual on subjective experiences and personality traits on participants of a center specialized in the treatment of substance use disorder in Uruguay. When comparing the psychological traits of ayahuasca participants to a control group, quantitative results using the Zuckerman-Kuhlman-Aluja Personality Questionnaire showed statistically significant higher scores in Impulsive Sensation Seeking, Boredom Susceptibility, and Social Warmth scales...
May 4, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35616606/systematic-review-of-psychometric-instruments-used-in-research-with-psychedelics
#6
REVIEW
Alexandre Augusto de Deus Pontual, H G Senhorini, C M Corradi-Webster, L F Tófoli, D Daldegan-Bueno
There has been a revival of research that studies the subjective effects of psychedelic drugs on humans. Areas of health science have been studying their possible therapeutic benefits, and psychological measurement instruments are being developed as the studies progress. However, these instruments currently suffer criticism regarding their number and evidence of psychometric quality. This study aims to review which psychometric instruments are available to assess subjective states induced by psychedelics. We systematically searched five databases (Web of Science, Academic Search Premier, EMBASE, CINAHL and PubMed) using psychometrics and psychedelics related terms identifying studies published from 1990 to 2021...
May 26, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35635152/ayahuasca-and-public-health-ii-health-status-in-a-large-sample-of-ayahuasca-ceremony-participants-in-the-netherlands
#7
JOURNAL ARTICLE
Maja Kohek, Genís Ona, Michiel van Elk, Rafael Guimarães Dos Santos, Jaime E C Hallak, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso
Ayahuasca is a plant decoction in traditional Amazonian medicine. Its ritual use has been internationalized, leading to policy challenges that countries should address. This study evaluates the impact of regular ayahuasca ceremony participation on health by assessing the health status of 377 participants in ayahuasca ceremonies in the Netherlands using validated health indicators. A questionnaire was developed and administered to study participants. The questionnaire included several health indicators with public health relevance (e...
May 28, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35640052/-spice-was-made-by-the-devil-himself-a-thematic-analysis-of-the-experience-of-an-addiction-to-synthetic-cannabinoids
#8
JOURNAL ARTICLE
Blessing N Marandure, Samson Mhizha, Amanda Wilson
Synthetic cannabinoids (SC) are the most common type of new psychoactive substances used predominantly as a replacement for cannabis. There is a wealth of literature on the negative effects experienced by users of SC. However, there is a paucity of research on the experience of addiction to SC from the users' perspectives. The present study qualitatively explored the experience of addiction to SC. Online blog entries detailing the experience of SC addiction were analyzed using thematic analysis. Users reported being stuck in a cycle of addiction which was composed of addiction hallmarks...
2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35694791/psychedelic-microdosing-mindfulness-and-anxiety-a-cross-sectional-mediation-study
#9
JOURNAL ARTICLE
Vincent Hartong, Arnold van Emmerik
While anecdotal reports claim that psychedelic microdosing reduces anxiety and mood symptoms, evidence supporting these claims is scarce. This cross-sectional study investigated the association between microdosing and trait anxiety. Furthermore, it was investigated if trait mindfulness mediated this association. Participants completed anonymous online questionnaires and were divided into three groups: current microdosers ( n = 186), former microdosers ( n = 77) and microdosing-naïve controls ( n = 234)...
2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/35950817/naturalistic-psychedelic-use-a-world-apart-from-clinical-care
#10
JOURNAL ARTICLE
Nicolas G Glynos, Christopher W Fields, Julie Barron, Moss Herberholz, Daniel J Kruger, Kevin F Boehnke
Interest in and availability of psychedelics for therapeutic purposes has increased in recent decades. In a large, anonymous, online survey, we investigated patterns of communication with healthcare providers and awareness and utilization of substance testing kits or services among people using psychedelics naturalistically. The sample population included attendees of a psychedelic activism event and users of psychedelic social media forums. Among 1,435 participants, 72.5% never discussed psychedelic use with their primary care provider (PCP)...
August 11, 2022: Journal of Psychoactive Drugs
https://read.qxmd.com/read/34607532/homebrewed-psilocybin-can-new-routes-for-pharmaceutical-psilocybin-production-enable-recreational-use
#11
JOURNAL ARTICLE
William J Gibbons, Madeline G McKinney, Philip J O'Dell, Brooke A Bollinger, J Andrew Jones
Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction. This growing interest has led to many recent advancements in psilocybin synthesis strategies, including multiple in vivo fermentation-based approaches catalyzed by recombinant microorganisms. In this work, we show that psilocybin can be produced in biologically relevant quantities using a recombinant E...
December 2021: Bioengineered
https://read.qxmd.com/read/34166299/ayahuasca-improves-self-perception-of-speech-performance-in-subjects-with-social-anxiety-disorder-a-pilot-proof-of-concept-randomized-placebo-controlled-trial
#12
RANDOMIZED CONTROLLED TRIAL
Rafael G Dos Santos, Flávia de Lima Osório, Juliana Mendes Rocha, Giordano Novak Rossi, José Carlos Bouso, Lucas S Rodrigues, Gabriela de Oliveira Silveira, Mauricio Yonamine, Jaime E Cecílio Hallak
BACKGROUND: Ayahuasca is a classic hallucinogen with anxiolytic and antidepressive properties. Anecdotal evidence also suggests that it improves performance (eg, singing, speech). This controlled trial assessed the effects of ayahuasca on speech performance and anxiety in individuals with social anxiety disorder. METHODS: Seventeen volunteers with social anxiety disorder participated in a pilot, proof-of-concept, randomized, parallel-group trial. Self-perception of performance during a public-speaking test was assessed with the Self-statements During Public Speaking Scale primary outcome)...
September 2021: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/34497503/endocannabinoid-modulation-of-nucleus-accumbens-microcircuitry-and-terminal-dopamine-release
#13
REVIEW
Dan P Covey, Alyssa G Yocky
The nucleus accumbens (NAc) is located in the ventromedial portion of the striatum and is vital to valence-based predictions and motivated action. The neural architecture of the NAc allows for complex interactions between various cell types that filter incoming and outgoing information. Dopamine (DA) input serves a crucial role in modulating NAc function, but the mechanisms that control terminal DA release and its effect on NAc neurons continues to be elucidated. The endocannabinoid (eCB) system has emerged as an important filter of neural circuitry within the NAc that locally shapes terminal DA release through various cell type- and site-specific actions...
2021: Frontiers in Synaptic Neuroscience
https://read.qxmd.com/read/34630182/effects-of-appearance-and-performance-enhancing-drugs-on-personality-traits
#14
REVIEW
Simona Zaami, Adele Minutillo, Ascanio Sirignano, Enrico Marinelli
Appearance- and performance-enhancing drugs (APEDs) are commonly used by adolescents and young adults in an effort to improve not only athletic performance but also physical and mental efficiency and sexual appearance. The rationale for using these drugs is grounded in the perceived importance of external appearance, the quest for health and youth, and the urge to boost one's sexual performances. Although APED users tend to be quite moderate overall, some specific subpopulations can display pathological use associated with high-risk behaviors...
2021: Frontiers in Psychiatry
https://read.qxmd.com/read/34646176/mdma-assisted-therapy-as-a-means-to-alter-affective-cognitive-behavioral-and-neurological-systems-underlying-social-dysfunction-in-social-anxiety-disorder
#15
REVIEW
Jason Luoma, M Kati Lear
Social anxiety disorder (SAD) is a prevalent and often debilitating psychiatric disorder that can assume a chronic course even when treated. Despite the identification of evidence-based pharmacological and behavioral treatments for SAD, much room for improved outcomes exists and 3,4-methylenedioxymethamphetamine (MDMA) has been proposed as a promising adjunctive treatment to psychological interventions for disorders characterized by social dysfunction. A small randomized, placebo-controlled trial of MDMA-assisted therapy (MDMA-AT) for social anxiety in autistic adults offered encouraging results, but more research is sorely needed to explore the potential for MDMA-AT in treating SAD...
2021: Frontiers in Psychiatry
https://read.qxmd.com/read/34266621/any-questions-a-sober-look-at-mdma
#16
JOURNAL ARTICLE
Luke G Petry, Monica Sharma, Aaron S Wolfgang, David A Ross, Joseph J Cooper
No abstract text is available yet for this article.
August 1, 2021: Biological Psychiatry
https://read.qxmd.com/read/30426556/prohedonic-properties-of-gamma-hydroxybutyrate-are-associated-with-changes-in-limbic-resting-state-functional-connectivity
#17
RANDOMIZED CONTROLLED TRIAL
Oliver G Bosch, Fabrizio Esposito, Dario Dornbierer, Robin von Rotz, Rainer Kraehenmann, Philipp Staempfli, Boris B Quednow, Erich Seifritz
OBJECTIVE: Gamma-hydroxybutyrate (GHB) is an endogenous GHB-/GABA-B receptor agonist and a narcolepsy treatment. However, GHB is also abused for its prohedonic effects. On a neuronal level, it was shown that GHB increases regional cerebral blood flow in limbic areas such as the right anterior insula (rAI) and the anterior cingulate cortex (ACC). We aimed to further explore the association between the subjective and neuronal signatures of GHB. METHOD: We assessed subjective effects and resting-state functional connectivity (rsFC) of an rAI- and an ACC-seed in 19 healthy male subjects after GHB (35 mg/kg p...
November 2018: Human Psychopharmacology
https://read.qxmd.com/read/30102081/psychedelics-as-anti-inflammatory-agents
#18
JOURNAL ARTICLE
Thomas W Flanagan, Charles D Nichols
Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way these compounds are perceived in the medical community and populace at large. One emerging therapeutic area that holds significant promise is their use as anti-inflammatory agents...
August 2018: International Review of Psychiatry
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.